AU3847997A - Inhibitors of the interaction between P53 and MDM2 - Google Patents

Inhibitors of the interaction between P53 and MDM2

Info

Publication number
AU3847997A
AU3847997A AU38479/97A AU3847997A AU3847997A AU 3847997 A AU3847997 A AU 3847997A AU 38479/97 A AU38479/97 A AU 38479/97A AU 3847997 A AU3847997 A AU 3847997A AU 3847997 A AU3847997 A AU 3847997A
Authority
AU
Australia
Prior art keywords
compounds
mdm2
interaction
human
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38479/97A
Other languages
English (en)
Inventor
Angelika Bottger
Volker Bottger
Patrick Chene
Pascal Furet
Carlos Garcia-Echeverria
Heinz-Kurt Hochkeppel
David Lane
Stephen Picksley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of AU3847997A publication Critical patent/AU3847997A/en
Priority to AU14979/01A priority Critical patent/AU777766B2/en
Assigned to CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED reassignment CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED, NOVARTIS AG
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AU38479/97A 1996-07-05 1997-07-04 Inhibitors of the interaction between P53 and MDM2 Abandoned AU3847997A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14979/01A AU777766B2 (en) 1996-07-05 2001-01-15 Inhibitors of the interaction between p53 and MDM2

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9614197 1996-07-05
GBGB9614197.3A GB9614197D0 (https=) 1996-07-05 1996-07-05
GB9707041 1997-04-07
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2
PCT/EP1997/003549 WO1998001467A2 (en) 1996-07-05 1997-07-04 Inhibitors of the interaction between p53 and mdm2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU14979/01A Division AU777766B2 (en) 1996-07-05 2001-01-15 Inhibitors of the interaction between p53 and MDM2

Publications (1)

Publication Number Publication Date
AU3847997A true AU3847997A (en) 1998-02-02

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38479/97A Abandoned AU3847997A (en) 1996-07-05 1997-07-04 Inhibitors of the interaction between P53 and MDM2

Country Status (8)

Country Link
EP (1) EP0958305B1 (https=)
JP (1) JP2001500365A (https=)
AT (1) ATE397621T1 (https=)
AU (1) AU3847997A (https=)
CA (1) CA2259149A1 (https=)
DE (1) DE69738754D1 (https=)
NZ (1) NZ333609A (https=)
WO (1) WO1998001467A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
WO1998051707A1 (fr) * 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
AU4052399A (en) * 1998-05-26 1999-12-13 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
CA2514374A1 (en) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
DE602004024831D1 (de) * 2004-04-22 2010-02-04 Ortho Mcneil Pharm Inc Hdm2-inhibitorkomplexe und verwendungen davon
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SG176783A1 (en) * 2009-06-16 2012-01-30 Univ Tokai Anti-gram-negative bacteria agent
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
MX351012B (es) * 2011-11-09 2017-09-28 Merz Pharma Gmbh & Co Kgaa Neurotoxinas que exhiben actividad biologica acortada.
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
US20200354413A1 (en) 2017-12-15 2020-11-12 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
US20220153868A1 (en) * 2019-02-20 2022-05-19 Oncolyze, Inc Hdm2 antibody for use in treating cancer
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
EP4312749A4 (en) * 2021-03-31 2025-07-09 Zeteo Tech Inc DIAGNOSIS OF RESPIRATORY DISEASES BY CAPTURE OF AEROSOLIZED BIOMATERIAL PARTICLES USING FIXED BED SYSTEMS AND METHODS
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Also Published As

Publication number Publication date
WO1998001467A2 (en) 1998-01-15
EP0958305A2 (en) 1999-11-24
ATE397621T1 (de) 2008-06-15
JP2001500365A (ja) 2001-01-16
EP0958305B1 (en) 2008-06-04
NZ333609A (en) 2000-08-25
CA2259149A1 (en) 1998-01-15
DE69738754D1 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
AU4612093A (en) Soluble ligands for CD40
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
MX9707431A (es) Inhibidores de la proteina cinasa c.
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
GR3035936T3 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
AU6933496A (en) Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
GB2322132A (en) Keratinocyte growth factor-2 products
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
WO2005123760A3 (en) Treating cancer
EP0821969A3 (en) Medicinal Composition comprising TCF-II
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
AU2001220255A1 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector
TW368393B (en) Poison bait for controlling noxious insects

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted
PC1 Assignment before grant (sect. 113)

Owner name: CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED

Free format text: THE FORMER OWNER WAS: NOVARTIS AG, CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED